1
Clinical Trials associated with LD PepGNP-SARSCoV2(Emergex Vaccines Holding)A Phase-I, Double-blind, Randomized, Vehicle-controlled, Dose-finding, Safety Study of a Synthetic Nanoparticle-based, T Cell Priming Peptide Vaccine Against SARS-CoV-2 in Healthy Adults in Switzerland
This trial is Stage 2 of a 2-part adaptive trial. The study aims to investigate the safety of 2 doses of a T-cell priming specific cocktail of Coronaviruses peptides mounted on a gold nanoparticle.
Note: Stage 1 of the 2-part adaptive trial, testing a specifically selected mix of Dengue virus peptides, commenced Aug 2021. This is now in follow up (NCT04935801).
100 Clinical Results associated with LD PepGNP-SARSCoV2(Emergex Vaccines Holding)
100 Translational Medicine associated with LD PepGNP-SARSCoV2(Emergex Vaccines Holding)
100 Patents (Medical) associated with LD PepGNP-SARSCoV2(Emergex Vaccines Holding)
100 Deals associated with LD PepGNP-SARSCoV2(Emergex Vaccines Holding)